Transcatheter repair wins for severe tricuspid regurgitation
MUNICH — A strategy of transcatheter tricuspid valve repair on top of optimal medical therapy was superior to medical therapy alone for patients with symptomatic severe tricuspid regurgitation and heart failure, according to new data.
In addition to improvements in quality of life previously seen in tricuspid valve repair trials, the interventional was associated with meaningful reductions in all-cause death and HF hospitalization — benefits that emerged early and were sustained up to 3 years, researchers reported at the European Society of Cardiology Congress.
“For most of